Innovation

A Novel Epitope Tag and Highly Sensitive Monoclonal Antibodies for Improved Immunodetection of Tagged Proteins

The Rockefeller University
posted on 01/26/2010

Researchers studying certain proteins of interest require tools to detect these proteins with regards to their location in the cell and/or tissues, and also to be able to purify them. The method of epitope tagging is a tool commonly used for these purposes and involves adding a molecular tag that can then be recognized by an antibody against that tag. This method is particularly useful in the many cases where there are no antibodies specific to the protein of interest. Our scientists have prepared a number of monoclonal antibodies (mAbs) against recombinant mouse Langerin, which also contained a linker sequence from the E. coli protein OmpF and a FLAG epitope. In doing so, they have identified two mAbs that were not reactive to Langerin, but show remarkable efficacy in immunodetection methods. The L5 mAb recognizes the FLAG epitope, and has been shown to be better than many conventional anti-FLAG mAbs, while the OLLA-2 mAb recognizes a novel epitope named OLLAS with great sensitivity. These novel reagents are ideal for immunodetection of tagged proteins and have great potential to be valuable research tools.

Suggested Uses

Epitope tagging and immunodetection of tagged proteins

Innovation Details
 

File Number: RU 848 

Other Information: Principal Investigator: Dr. Ralph M. Steinman & Dr. Chae Gyu Park Park, S.H., et al. 2008. J. Immunol. Methods, 331:27-38.


IP Protection


License Online

This innovation currently is not available for online licensing. Please contact Nidhi Sabharwal at The Rockefeller University for more information.

Request more info via email request more info
People

Case Manager:

Nidhi Sabharwal Nidhi Sabharwal

Innovations (62)


Download Technology Brief (PDF)


Followed By

Follow this innovation



No one is following this innovation.

Organization
Communities
Profile
Related Tags

Find more innovations


February 11, 2009

8,805 members 16,684 innovations 159 organizations

Browse

David Kolb, CEO and chairman of the board, Emunamedica LLC.

"We found tremendous value and benefit in using the iBridge Network..."  read more...